MCG technology has earned the respect and support of many leading figures in the medical community, including Mr. Peter Nichols, current chairman of the board of Boston Scientific Corporation and Dr. Eberhard Grube, chief of cardiology and angiology at the Siegburg Heart Center in Germany.

Some of our clients and supporters have been kind enough to offer their views on the clinical utility and future potential of the Premier Heart technology, a selection of which have been reproduced below.

For additional information you may contact us, or contact one of our clients.

Clinical Users

Dr. Charles K. Micelli, M.D., F.A.C.P., F.A.A.C., F.C.C.P.
Massapequa, NY

Dr. Micelli has been using MCG technology since early 2008, and has incorporated it into his daily practice as a major tool for the detection of coronary artery disease. He has praised the MCG system as "an invaluable tool which is on the cutting edge of technology", seeing MCG as "a major breakthrough that will revolutionize cardiology".

Dr. Micelli's reference letter

Dr. Franz Ritucci, M.D.
Orlando, FL

Dr. Ritucci is a front-line physician specializing in Urgent Care and Emergency Medicine. His team has been using the MCG system since January of 2008, and has been a strong advocate of its use in the Emergency and Urgent Care settings.

Dr. Ritucci has noted that MCG "is able to identify patients . . . with significant coronary stenosis" in cases where traditional diagnostic modalities, with the MCG diagnosis subsequently validated through cardiac catheterization. Additionally, he has praised the high negative predictive value of the MCG system, "which is beneficial in preventing patients with an abnormal or equivocal stress test from having to undergo costly catheterization"

Dr. Howard L. Sacher, M.D.
Massapequa, NY

Dr. Sacher and his colleagues began using the MCG system in mid-2008 as part of their suite of tools for diagnosing coronary artery disease. They have found the MCG results to correlate with their expectations based on clinical indicators and risk factors.

Dr. Sacher's Reference Letter

Dr. H. Robert Silverstein, M.D., F.A.C.C.
Hartford, CT

Dr. Silverstein was one of MCG's earliest clinical users, and has been using our MCG system for seven years. In his appraisal of the MCG system Dr. Silverstein noted that "it is the uncanny ability of the MCG EKG to reveal safety as well as danger", noting that in his experience our technology is "secondary only to a coronary angiogram".

Dr. Silverstein's Reference Letter

Dr. John E. Strobeck, M.D., Ph.D.
Hawthorne, NJ

Dr. Strobeck is the founder and medical director of Heart-Lung Associates of America, one of America's leading cardiac care specialty groups. He has been using MCG's technology in his practice since February of 2008, and has been an outspoken advocate of the benefits of the MCG technology for both detecting and ruling out coronary artery disease.

Dr. Strobeck "was astounded by the accuracy with which [MCG] was able to identify patients . . . with significant coronary stenosis", particularly in cases where other conventional diagnostic tools produced negative results. He has also praised the ability of MCG analysis to detect conditions in patients with normal results from traditional diagnostic tools.

Dr. Strobeck's Reference Letter

Academic Supporters

Dr. Wilbert Aronow, M.D., F.A.C.C.
Division of Cardiology, Westchester Medical Center, NY

Dr. Aronow is a Professor of Medicine at New York Medical College and head of teaching and clinical cardiology at Westchester Medical Center. He is also a renowned researcher and editor of many peer-reviewed medical journals.

Dr. Arronow reviewed the data from MCG's first clinical trial at Westchester Medical Center.

Dr. Eberhard Grube, M.D.
Chair of Dept. of Cardiology, Siegburg Heart Center, Germany

Dr. Grube is Chief of the Department of Cardiology and Angiology at the Siegburg Heart Center, as well as a Consulting Professor of Medicine at Stanford University. He is internationally renowned as an innovator in the development and testing of new devices and procedures in cardiology, and has taken the lead in clinical testing of drug-eluting stents, percutaneous closure devices and catheter-based valve surgery.

Dr. Grube was the principal investigator of MCG clinical trials at the Siegburg heart center, and co-authored several articles discussing the results of that trials.

Dr. Michael Imhoff, M.D., Ph.D.
Dept. for Medical Informatics, Biometrics & Epidemiology, Ruhr University, Germany

Dr. Imhoff is a board certified surgeon and intensivist with 18 years clinical practice in one of the largest hospitals in Europe. He also holds a Ph.D. in Medical Informatics and Statistics, and serves as a strategic consultant to Dräger Medical and Siemens Medical.
His research covers substantial portions of the medical field including surgical intensive care medicine, patient monitoring and clinical data management, statistical analysis of patient and trial data, and the application of artificial intelligence in medicine.

Dr. Imhoff has performed an extensive analysis of MCG clinical trial data in his capacity as a consultant to Dräger Medical and Siemens Medical, and has co-authored several articles analyzing the clinical efficacy of the MCG technology.

Dr. Kotaro Obunai, M.D.
Dept. of Cardiology, New York Presbyterian Hospital-Columbia University Med. Center

Dr. Obunai has reviewed data from MCG's clinical trial meta analysis, summarizing results and trends across our clinical trials through 2008. He has praised the results of MCG testing, noting that it has "the highest accuracy result I've ever seen ... with non-invasive testing", especially noting its high accuracy in women.

Dr. Obunai's email

Dr. Kazuko Tajiri, M.D., Ph.D.
Dept. of Cardiovascular & Internal Med. - Tsukuba University, Japan.

Dr. Tajiri is one of several cardiologists and internists who reviewed MCG's data during our initial research into the Asia-Pacific market. Among other comments, Dr. Tajiri noted that the MCG system was "ground-breaking", describing it as "a useful tool for the diagnosis of ischemic heart disease" and praising both its current results and future potential.